Recurrent translocations involving the MLL gene on chromosome band 11q23 together with diverse partners have been reported in both acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). 1 Most translocations occur in the 8.3 kb breakpoint cluster region (BCR) of the MLL gene, between exons 8 and 12. The same region is also affected by a second MLL alteration, a partial tandem duplication (PTD) repeating the 5 0 part of the gene ( Figure 1 ). MLL PTD is associated with a poor prognosis, 2 but how mutated MLL contributes to leukemogenesis is not well understood. Continuous cell lines have often helped to understand better how gene alterations influence the fate of a cell.
Since there has been no report of cell lines carrying MLL PTD, we set out to screen a panel of cell lines (66 AML, 73 ALL) for this mutation. The ALL-derived cell lines were included, although to our knowledge no ALL cases with MLL PTD have yet been described. However, the MLL BCR is affected by both translocations and PTD, and MLL translocations are common not only in AML but also in ALL.
1,3 Therefore, we reasoned that ALL-derived cell lines might also carry the MLL PTD.
We performed reverse-transcriptase polymerase chain reaction (RT-PCR) analysis to detect expression of MLL wt and MLL PTD (Figures 1 and 2) . MLL wt was shown to be widely expressed in acute leukemia-derived cell lines: 138/139 cell lines expressed MLL wt mRNA ( Figure 2 ). ML-2 was the only cell line without detectable MLL wt transcripts (Figure 2 ). This cell line had previously been shown to carry a t(6;11) and to have lost the second MLL allele. Interestingly, two of the four cell lines with MLL PTD had previously been shown to carry MLL translocations. 5, 6 We confirmed by RT-PCR and sequencing analysis that cell lines CTS and UG-3 carried t(6;11) and t(9;11), respectively. Both cell lines exhibited just one altered MLL band in Southern blot analysis in addition to the MLL WT band -and this not only after digestion with BamHI, but also with HindIII ( Figure 3 ). Attempts to elucidate the cause of this phenomenon by long-range RT-PCR were not successful. Wild-type status of exons was confirmed by RT-PCR using primers 9 frw and 14 rev. MLL PTD, fusing exon 3 and subsequent exons to the BCR, were detected applying primers 9 frw and 4 rev. For detection of translocations, MLL primer 8 frw was used together with a reverse primer specifically recognizing the respective translocation partner.
Figure 2
MLL PTD in acute leukemia-derived cell lines. 4/139 acute leukemia-derived cell lines (CTS, EOL-1, MUTZ-11 and UG-3) expressed MLL PTD, as assessed by RT-PCR using primers 9 frw and 4 rev (see Figure 1) . Cell line OCI-AML-2 was included as the wild-type control. Cell line ML-2 is the only cell line not expressing the wildtype form of MLL (RT-PCR with primers 9 frw and 14 rev). The cDNA quality of this cell line has been confirmed by detection of ABL transcripts (not shown).
Figure 3
Alterations of the MLL gene. Results of MLL PTD RT-PCR were reanalyzed by Southern blot analysis. The product of MLL wildtype RT-PCR (spanning exons 9-14) was used as
The aim of this study was to find cell lines with MLL PTD. RT-PCR indicated that 4/139 acute leukemia-derived cell lines carried this genetic alteration, all of them AML-derived. Cell line MUTZ-11 appears to be of special interest as this cell line not only carries an MLL PTD but also an FLT3 ITD (internal tandem duplication of fms-like tyrosine kinase).
7 FLT3 ITD, like MLL PTD, has been shown to be associated with an unfavorable prognosis, and simultaneous occurrence of both genetic alterations had already been described in patients.
Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia 
TO THE EDITOR
The glutathione S-transferase (GSTs) superfamily of enzymes catalyzes the conjugation of xenobiotics and potentially damaging oxidative metabolites with glutathione. Four major subfamilies of GSTs (a, m, p, y) can be distinguished in humans.
Several studies implicate GST polymorphisms in de novo cancer as well as cancers that are secondary to chemotherapy. In all cases, GST deficiency, rather than high GST activity, has been associated with an increased risk of cancer. However, because of its activity, GST has been associated with cancer-drug resistance, while GST deficiency of GSTT1 and GSTM1 could positively influence chemotherapeutic efficacy in some patients. 1 In the case of childhood acute lymphoblastic leukemia (ALL), conflicting results have been reported on the associations between GSTM1 and GSTT1 genotypes and outcome. 2, 3 Stanulla et al. 4 recently showed a two-fold and 2.8-fold reduction in risk of relapse, respectively, relative to the presence of the GSTM1 or GSTT1. These findings encouraged the evaluation of the GST genotypes contribution to therapeutic outcome in larger, well-characterized ALL patient populations prospectively enrolled in the same protocol treatment. After informed consent, 356 patients were enrolled in the study here reported. Patients were treated within the AIEOP ALL 95 study. 5 The outcome of the 356 patients described here was similar to that of the 1360 patients enrolled in the whole AIEOP ALL 95 study [event-free survival (EFS) at 5 years of 76.0 (s.e. 2.0) vs 74.2 (s.e. 1.8), (P-value ¼ 0.88)], showing that no selection bias was present in the enrollment of patients in the present study. Genotypes for GSTM1 and GSTT1 (homozygous/heterozygous ¼ wild type; homozygous deletion ¼ null) were determined by polymerase chain reaction (PCR), as described by Chen et al, 3 by using DNA extracted from bone marrow mononuclear cell samples. Figure 1 shows the EFS curves in patients according to different GST(s) genotypes. The analysis was restricted to 323 patients with full GST genotypes data. No significant difference in EFS was observed either by the univariate analyses or when the effect was adjusted by known prognostic factors in the Cox model. Since null genotype could increase the risk of toxicity death while decreasing the risk of relapse, the analysis of the risk of relapse was performed separately. The incidence curves represented in Figure 1 
